^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
NMS-293
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Nerviano Medical Sciences
Drug class:
PARP1 inhibitor
Related drugs:
Phase 1
Nerviano Medical Sciences
Active, not recruiting
Last update posted :
04/22/2024
Initiation :
11/25/2019
Primary completion :
03/31/2023
Completion :
12/30/2024
HER-2 • BRCA1 • BRCA2 • BRCA
|
BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA1 mutation + BRCA2 mutation
|
NMS-293
Phase 1/2
Nerviano Medical Sciences
Recruiting
Last update posted :
03/15/2024
Initiation :
12/01/2021
Primary completion :
06/30/2025
Completion :
11/30/2025
EGFR • IDH1 • IDH2 • MGMT • TERT
|
EGFR mutation • EGFR amplification • MGMT promoter methylation • TERT mutation • IDH wild-type • TERT promoter mutation
|
temozolomide • lomustine • NMS-293
Share
